I can see many reasons to be jolly on the regenerative medicine front as we get deeper into the holiday season as there is quite a lot of stem cell good news even if there is also some not so good news. In today’s post the focus is on the good news of late. Semma […]
Stem cell good news for the holidays: biotechs, FDA, organoids Read More »
Is there a proliferating stem cell fake news problem in the biotech world? More broadly, the SEC is cracking down on the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news. Hyped press releases (PR)
Stem cell fake news driving biotech investors or vice versa…or what? Read More »
I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly comprehensive. I’m also curious what readers think are the most promising ones and why. So weigh in with comments please or
What is your favorite stem cell/regen med biotech & why? Read More »
A stem cell biotech in the news this week was one that had mostly flown under the radar previously with aim to zap cancer stem cells. Stemcentrx has a focus on killing cancer stem cells as a novel approach to treating cancer. Antonio Regalado had a nice article yesterday on the company. He reports that Stemcentrx has
Can Stemcentrx thrive as a biotech killing cancer stem cells? Read More »
The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical
Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »
A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston
New biotech Semma Therapeutics stem cell diabetes arena Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
What is the valley of death of science and biotech? For those of us conducting stem cell research, especially human stem cell research, I don’t have to tell you how expensive it is. Even just doing pre-clinical or basic science research costs a fortune. When you start talking about the kind of pre-clinical research specifically
The valley of death: stem cells, biotechs, and money Read More »
The Trump Administration just quickly gutted the FDA including key leadership. What is going to be the impact of this sudden purge? Former Commissioner Robert Califf recently said it is the end of the FDA as we’ve known it. Those are dramatic words, but they seem on the money to me. As a biomedical scientist
Why the FDA & CBER leadership purge will be so bad for biotech Read More »
A new Florida stem cell bill directly challenges the FDA and its CBER branch. If passed, which seems relatively likely, the Florida bill would become of state trend. A Utah stem cell law and a broader Nevada biologics law legally okay non-FDA approved biologics. These and other pending state efforts pose major risks to FDA
Florida stem cell bill is part of state trend to sidestep FDA Read More »